Jeremy Chrisp
Gründer bei EpiAxis Therapeutics Pty Ltd.
Profil
Dr. Jeremy Chrisp has over 21 years experience in the Australian healthcare market as a scientist, marketer, senior manager, consultant and entrepreneur in the pharmaceutical, medical device and life-science fields.
He gained this experience by working with leading global multinational companies, including Merck & Co, Stryker, Becton Dickinson & Medtronic.
Dr. Chrisp held positions including clinical research associate, sales representative, and product manager, marketing manager, business development manager, sales and marketing manager as well as managing director.
Until recently, he was the CEO of Medsaic Pty Ltd, a spin-out company from The University of Sydney that commercialised a new antibody micro-array platform for the diagnosis of disease by the identification of surface proteins.
He is also the founder and Managing Director of Jeremy Chrisp & Associates, a biotechnology consultancy company with a focus on start-up ventures.
Dr. Chrisp has extensive market experience: including both capital equipment and single use medical devices, diagnostics, surgical implants and therapeutics, covering disciplines such as anaesthetics, general surgery, minimally invasive surgery, orthopaedics, cardiology, respiratory medicine, immunology and ophthalmology.
Jeremy holds a B.Sc (Hons) in physiology from the University of Otago (NZ) and PhD in physiology from the University of Canterbury (NZ).
He is also a member of the Australian Institute of Company Directors.
Aktive Positionen von Jeremy Chrisp
Unternehmen | Position | Beginn |
---|---|---|
Beta Therapeutics Pty Ltd.
Beta Therapeutics Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Beta Therapeutics Pty Ltd. develops new diabetes therapeutics based on key discoveries. It generates preventative and potentially curative therapies for the people who suffer from diabetes. The company was founded by Keats Nelms, Chris Parish and Charmaine Simeonovic in 2011 and is headquartered in Canberra, Australia. | Direktor/Vorstandsmitglied | - |
EpiAxis Therapeutics Pty Ltd.
EpiAxis Therapeutics Pty Ltd. BiotechnologyHealth Technology EpiAxis Therapeutics Pty Ltd. engages in biotechnology company. It pursuing a preclinical and clinical drug development program directed at the prevention of metastatic disease by targeting the pivotal enzyme system controlling the proliferation of cancer stem cells. The company was founded by Jeremy Chrisp and Sudha Rao and is headquartered in Canberra, Australia. | Gründer | - |
Ehemalige bekannte Positionen von Jeremy Chrisp
Unternehmen | Position | Ende |
---|---|---|
ANU Connect Ventures Pty Ltd.
ANU Connect Ventures Pty Ltd. Investment ManagersFinance ANU Connect Ventures Pty Ltd (ANU Connect Ventures) is a venture capital subsidiary of Australian National University founded in 2005. The firm is headquartered in Canberra, Australia. | Private Equity Investor | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
ANU Connect Ventures Pty Ltd.
ANU Connect Ventures Pty Ltd. Investment ManagersFinance ANU Connect Ventures Pty Ltd (ANU Connect Ventures) is a venture capital subsidiary of Australian National University founded in 2005. The firm is headquartered in Canberra, Australia. | Finance |
Beta Therapeutics Pty Ltd.
Beta Therapeutics Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Beta Therapeutics Pty Ltd. develops new diabetes therapeutics based on key discoveries. It generates preventative and potentially curative therapies for the people who suffer from diabetes. The company was founded by Keats Nelms, Chris Parish and Charmaine Simeonovic in 2011 and is headquartered in Canberra, Australia. | Commercial Services |
EpiAxis Therapeutics Pty Ltd.
EpiAxis Therapeutics Pty Ltd. BiotechnologyHealth Technology EpiAxis Therapeutics Pty Ltd. engages in biotechnology company. It pursuing a preclinical and clinical drug development program directed at the prevention of metastatic disease by targeting the pivotal enzyme system controlling the proliferation of cancer stem cells. The company was founded by Jeremy Chrisp and Sudha Rao and is headquartered in Canberra, Australia. | Health Technology |